How do you market medical devices to vascular surgeons?

Market to vascular surgeons by leading with real-world outcomes data (including registry and VQI comparisons), addressing both open and endovascular procedure contexts, building conference presence at SVS VAM and VIVA, and supporting hands-on training through simulation and proctoring programs. For devices suited to the office-based lab setting, build a separate economic case that addresses OBL-specific reimbursement and cost-per-case.

What conferences reach vascular surgeons?

The Society for Vascular Surgery Vascular Annual Meeting (VAM) is the primary national forum. VIVA is the leading endovascular-focused meeting. The VEITHsymposium is a respected academic endovascular forum. For international reach, LINC and CIRSE are the European equivalents. The right conference depends on your device's procedure category and target setting.

What is the SVS Vascular Quality Initiative and why does it matter for device marketing?

The Vascular Quality Initiative (VQI), maintained by the SVS, is the primary real-world outcomes registry for vascular procedures in the US. Vascular surgeons use VQI data to benchmark their outcomes and evaluate new devices. A company that can reference VQI registry comparisons in its marketing is speaking the language of the specialty. Favorable VQI-level evidence is more persuasive to this audience than a controlled trial conducted in highly selected patients.

What is the difference between marketing to vascular surgeons versus interventional cardiologists for the same device?

Vascular surgeons and interventional cardiologists often treat similar anatomical targets (peripheral arteries, renal arteries, carotid arteries) with similar devices, but they approach the clinical decision differently. Vascular surgeons are more likely to weigh the open surgical backup option and long-term durability data. Interventional cardiologists may prioritize catheter handling and rapid access. Their professional societies and conferences are different, their clinical training backgrounds differ, and messages that land with one audience may feel misaligned to the other.

How important is the office-based lab (OBL) segment for vascular device companies?

The OBL segment is a meaningful and growing part of the vascular market, particularly for peripheral arterial and venous procedures. Surgeons in OBLs make independent purchasing decisions, are sensitive to cost-per-case and reimbursement dynamics, and are not subject to the same hospital GPO and VAC constraints as employed surgeons. Companies with products suited to OBL procedures should have a distinct outreach and economic messaging strategy for this channel.

How does reimbursement affect vascular surgery device marketing?

Reimbursement is unusually influential in vascular surgery because many procedures are performed in both the hospital outpatient department (HOPD) and the OBL setting, where reimbursement rates differ significantly. CMS policy changes can shift case volume between settings and affect whether a procedure is financially viable outside a hospital. Device companies should understand the current reimbursement environment for their specific procedure category and be prepared to address reimbursement questions in their hospital and OBL conversations.

How to Market Medical Devices to Vascular Surgeons

To market medical devices to vascular surgeons, you must first understand that vascular surgery has undergone a fundamental technology shift over the past two decades. Most practicing vascular surgeons today do both open surgery and endovascular procedures, and the balance between those two continues to shift toward endovascular techniques. That transformation shapes everything about how they evaluate devices, which companies they pay attention to, and what evidence they require before adoption.

At Buzzbox Media, we work with medical device companies in surgical specialties. This guide covers who vascular surgeons are as device buyers, what drives their adoption decisions, the channels and conferences that reach them, and the common marketing errors that lose credibility with this audience.

Who the vascular surgeon buyer is

Vascular surgery is a distinct surgical specialty focused on diseases of the blood vessels outside the heart and brain. That scope covers arterial occlusive disease (carotid, aortic, peripheral arterial), aneurysm repair (abdominal aortic, and thoracic and thoracoabdominal aortic, the latter often shared with cardiac and cardiothoracic surgery), venous disease (varicose veins, chronic venous insufficiency, deep vein thrombosis), access for hemodialysis, and limb salvage for chronic limb-threatening ischemia.

The most important structural fact for device marketing is that most vascular surgeons are now trained and practice in both open and endovascular modalities. Fellowship training in vascular surgery includes endovascular techniques, and many vascular surgeons have added catheter-based skills through additional fellowship or structured training. The same surgeon who does an open aortic bypass on Monday may do an endovascular aneurysm repair (EVAR) on Tuesday. Device companies marketing stent grafts, catheters, guidewires, delivery systems, imaging, or hybrid room equipment reach this same surgeon.

Setting context: vascular surgeons practice in hospitals, academic medical centers, and increasingly in office-based endovascular labs (OBLs) and ambulatory surgery centers. The office-based setting has grown significantly for peripheral and venous procedures, and surgeons operating in their own OBL are simultaneously the clinical decision-maker and the business owner. That dual role changes what they weigh.

What vascular surgeons care about

Outcomes data in the relevant patient population. Vascular surgery patients are often older, comorbid, and high-risk. Evidence from a controlled trial population may not generalize well to the everyday vascular practice population. Surgeons want to see outcomes in real-world patient populations, including patients who would not have qualified for the pivotal trial. Registry data and real-world evidence studies carry significant weight.

Durability. Endovascular devices in particular are evaluated on long-term durability: freedom from reintervention, stent integrity, limb patency, and aneurysm sac behavior after EVAR. A device with a strong short-term profile but poor durability data will face skepticism from experienced vascular surgeons who have watched endovascular outcomes evolve over careers.

Device performance under real conditions. Vascular anatomy is variable and often challenging: tortuous iliac arteries, heavily calcified vessels, hostile neck morphology for EVAR. Device companies that demonstrate performance in anatomically challenging cases earn more credibility than those who present only best-case scenarios.

The open-to-endovascular balance. Vascular surgeons who do both modalities are watching how a device category affects their overall practice. A device that expands the treatable patient pool, allows treatment of patients previously requiring high-risk open surgery, or reduces the conversion-to-open rate is a compelling argument.

Economics in the OBL setting. Surgeons with office-based labs are acutely attentive to device cost, reimbursement per procedure, and supply-chain reliability. A device that pencils out in the OBL context is a different conversation from the same device used in a hospital setting where margins are absorbed differently.

How vascular surgeons evaluate a device

The SVS (Society for Vascular Surgery) Vascular Quality Initiative (VQI) registry is the most influential real-world data source in the specialty. Vascular surgeons compare new device data against VQI benchmarks, and companies that can show favorable comparison to registry benchmarks are at an advantage.

Peer influence operates at the society level. Presentations at the SVS Annual Meeting, VIVA (Vascular InterVentional Advances), and the Vascular Annual Meeting carry weight. A device outcome presented by a credible academic vascular surgeon at one of these meetings generates far more adoption momentum than a vendor brochure.

Hands-on experience with new delivery systems, stent-graft configurations, or catheter handling characteristics is a standard part of evaluation. Vascular surgery has a simulation and dry-lab infrastructure that device companies can work within. For complex aortic devices, preoperative planning with 3D modeling and sizing software is often part of the evaluation, and companies that provide sophisticated planning tools gain an advantage.

For OBL settings, the evaluation is also financial: the surgeon runs a cost model that factors device cost, procedure reimbursement, and volume.

The societies and conferences that reach vascular surgeons

Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM). VAM is the primary national meeting for US vascular surgeons and the most important forum for presenting clinical data, building exhibit presence, and sponsoring educational sessions. Device companies entering the vascular space treat VAM as a must-attend event.

VIVA (Vascular InterVentional Advances). VIVA is the key endovascular-focused meeting in the US, drawing vascular surgeons, interventional cardiologists, and interventional radiologists. For companies with endovascular or peripheral intervention products, VIVA often produces more targeted reach than VAM alone.

VEITH Symposium. The VEITHsymposium (held in New York each November) is a respected annual forum for endovascular discussion with strong academic surgeon attendance.

Society for Vascular Ultrasound (SVU) Annual Conference. For companies with vascular imaging or diagnostic ultrasound products, SVU is a relevant touchpoint, though its core audience is vascular technologists and sonographers as much as surgeons.

LINC (Leipzig Interventional Course) and CIRSE. For European market strategies, LINC and CIRSE (Cardiovascular and Interventional Radiological Society of Europe) are the equivalent high-reach forums. These are relevant for US companies building an international strategy.

Browse vascular and cardiovascular surgery events in the Buzzbox Media conference database to identify events by date and format: https://www.buzzboxmedia.com/conferences/.

The economic and purchasing context

The hospital purchasing context for vascular devices mirrors other surgical specialties: value analysis committees, GPO contracting, and supply-chain influence on which products are stocked. Vascular devices are also frequently included in service line negotiations, and a hospital that has committed to a platform (a particular EVAR system or a stent portfolio) carries contract pressure that a newcomer device must overcome.

The office-based lab context is distinctly different. The vascular surgeon in an OBL is making purchase decisions more like a small business owner: they control which products they stock, negotiate directly with distributors, and are sensitive to cost-per-case economics and reimbursement rates. Companies with products suited to the OBL setting should have a separate sales and marketing approach for this channel.

Reimbursement for peripheral interventions has been a flashpoint in vascular surgery. CMS reimbursement decisions affect whether a procedure is financially viable in the OBL or hospital outpatient department (HOPD) setting, and policy shifts have directly affected practice patterns. Device companies should understand the current reimbursement environment for their specific procedure category.

Messaging and channels that work

Registry-referenced outcomes. Leading a message with how your device performs relative to VQI benchmarks or published registry comparisons is the most credible opening for a vascular surgery audience.

Anatomical challenge messaging. Vascular surgeons handle the cases that don't fit the ideal. Demonstrating how your device performs in complex anatomies, hostile necks, calcified vessels, or small access vessels, addresses the real clinical question they face.

SVS and VIVA presence. These two conferences are the foundation of a vascular surgery marketing strategy. Scientific presence (podium data, published abstracts) matters more than booth size.

Endovascular technique education. Dry labs, simulation training, and proctored cases are how vascular surgeons adopt new catheter-based techniques and delivery systems. Supporting education is not ancillary to marketing; it is the primary adoption mechanism.

OBL-specific content and economics. If your device is suited for the office-based lab setting, build content that addresses the OBL economics, reimbursement, and case-selection criteria. This audience responds to business-case clarity alongside clinical evidence.

Digital content aligned to their searches. Vascular surgeons research specific procedures, anatomical challenges, and device comparisons online. Content that directly addresses these searches, and is findable through strong healthcare SEO, captures them during the evaluation window.

Buzzbox Media works with medtech companies to build search visibility and content strategy for surgical specialist audiences. Learn more about our medical device marketing services at https://www.buzzboxmedia.com/services/medical-device-marketing/.

Common mistakes when marketing to vascular surgeons

Ignoring the endovascular-open divide within the specialty. Marketing a device purely as an "open surgery" product to vascular surgeons who do 70 percent of their cases endovascularly, or vice versa, misreads how these surgeons actually practice. Most do both. Your message should be positioned relative to the procedure, not the modality stereotype.

Short-term data without durability signals. Vascular surgeons have watched endovascular devices succeed short-term and fail at five or ten years. Presenting only short-term data without acknowledging the durability question does not eliminate the concern; it raises it.

Missing the OBL context. A hospital-centric marketing strategy reaches only part of the vascular surgery market. The office-based lab segment is a distinct purchasing environment and a fast-growing channel for peripheral intervention. Missing it leaves volume on the table.

Conflating vascular surgeons with interventional cardiologists or interventional radiologists. All three specialties perform endovascular procedures, often in the same anatomical territory. They have different training backgrounds, different professional identities, and different clinical priorities. A message crafted for interventional cardiologists doing peripheral intervention does not land the same way with vascular surgeons, and vice versa.

Underinvesting in simulation and training. Vascular surgery has a strong simulation and dry-lab culture, particularly for complex aortic and peripheral techniques. Companies that do not invest in training infrastructure leave adoption incomplete. The training program is part of the product.